Supplementary Figure S2 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort

crossref(2024)

引用 0|浏览3
暂无评分
摘要

Supplementary Fig S2. Absolute neutrophil counts in patients who received prophylactic pegGCSF (A) and in patients who did not receive prophylactic peg-GCSF (B), by visit

更多
查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要